These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 8848665)

  • 1. [Prevention of coronary disease using pravastatin in men with hyperlipidemia].
    Evéquoz D
    Praxis (Bern 1994); 1996 Aug; 85(34):989-90. PubMed ID: 8848665
    [No Abstract]   [Full Text] [Related]  

  • 2. [Treatment of hyperlipidemia].
    Itakura H
    Nihon Naika Gakkai Zasshi; 1992 Nov; 81(11):1750-5. PubMed ID: 1336024
    [No Abstract]   [Full Text] [Related]  

  • 3. [Coronary mortality lowered by 24%. Convincing results of the LIPID Study on Secondary Prevention].
    Z Kardiol; 1998 Apr; 87(4 Suppl Uberzeugen):1-3. PubMed ID: 9618895
    [No Abstract]   [Full Text] [Related]  

  • 4. [Treatment of lipid disorders for coronary heart disease prevention according to International Atherosclerosis Society recommendations].
    Idzior-Waluś B
    Przegl Lek; 1999; 56(5):372-6. PubMed ID: 10554575
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Correction of atherogenic exogenously-induced postprandial hyperlipidemia with pravastatin].
    Bubnova MG; Aronov DM; Perova NV; Olfer'ev AM; Golubev MA; Mel'kina OE; Zhasminova VG
    Kardiologiia; 2002; 42(1):27-32. PubMed ID: 12494220
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Hyperlipidemia, coronary disease and antilipemic drugs--do they help?].
    Hansteen V
    Tidsskr Nor Laegeforen; 1995 Nov; 115(29):3602-3. PubMed ID: 8539711
    [No Abstract]   [Full Text] [Related]  

  • 7. A need to redefine the consensus on the use of statins in coronary heart disease prevention.
    Fruchart JC
    Eur Heart J; 2000 Oct; 21(19):1572-3. PubMed ID: 10988008
    [No Abstract]   [Full Text] [Related]  

  • 8. The pravastatin inflammation CRP evaluation (PRINCE): rationale and design.
    Albert MA; Staggers J; Chew P; Ridker PM;
    Am Heart J; 2001 Jun; 141(6):893-8. PubMed ID: 11376301
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effects of pravastatin on hospital admission in hypercholesterolemic middle-aged men: West of Scotland Coronary Prevention Study.
    J Am Coll Cardiol; 1999 Mar; 33(4):909-15. PubMed ID: 10091815
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The beneficial effects of lipid-lowering drugs beyond lipid-lowering effects: a comparative study with pravastatin, atorvastatin, and fenofibrate in patients with type IIa and type IIb hyperlipidemia.
    Saklamaz A; Comlekci A; Temiz A; Caliskan S; Ceylan C; Alacacioglu A; Yesil S
    Metabolism; 2005 May; 54(5):677-81. PubMed ID: 15877299
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overlap analysis of the West of Scotland coronary prevention study (WOSCOPS).
    Lim PO; Yee KM
    Circulation; 1999 Aug; 100(6):686. PubMed ID: 10441109
    [No Abstract]   [Full Text] [Related]  

  • 12. Clinical inquiries. What is the best strategy for monitoring the lipid-lowering effects of medical therapy used for the primary prevention of coronary artery disease (CAD)?
    Sherrod JP; Krist A
    J Fam Pract; 2001 Nov; 50(11):928. PubMed ID: 11711006
    [No Abstract]   [Full Text] [Related]  

  • 13. [Secondary prevention of coronary artery disease with lipid-lowering drugs].
    Delahaye F; De Gevigney G
    Ann Med Interne (Paris); 2001 Apr; 152(3):184-7. PubMed ID: 11431578
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changes of plasma inflammatory markers after withdrawal of statin therapy in patients with hyperlipidemia.
    Li JJ; Li YS; Chu JM; Zhang CY; Wang Y; Huang Y; Chen J; Yuan JQ; Huang YL
    Clin Chim Acta; 2006 Apr; 366(1-2):269-73. PubMed ID: 16343471
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Economic benefit analysis of primary prevention with pravastatin. Assumptions are methodologically flawed.
    Freemantle N; Mason J
    BMJ; 1998 Apr; 316(7139):1241-2. PubMed ID: 9583930
    [No Abstract]   [Full Text] [Related]  

  • 16. Is aggressive lipid lowering as effective as angioplasty in some cardiac patients?
    Drown DJ
    Prog Cardiovasc Nurs; 1999; 14(4):160-1. PubMed ID: 10689731
    [No Abstract]   [Full Text] [Related]  

  • 17. [Pravastatin and the development of diabetes mellitus. Evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study].
    Comaschi MA; Menozzi F
    Ital Heart J Suppl; 2001 May; 2(5):556-8. PubMed ID: 11388336
    [No Abstract]   [Full Text] [Related]  

  • 18. Dyslipidemia and coronary heart disease: management issues from Indian perspective.
    Gambhir DS; Gambhir JK; Sudha R
    Indian Heart J; 2000; 52(5):515-6, 617. PubMed ID: 11256772
    [No Abstract]   [Full Text] [Related]  

  • 19. Controversies in primary prevention among hyperlipidemic patients.
    McPherson R
    Can J Cardiol; 1999 Apr; 15 Suppl B():16B-19B. PubMed ID: 10350678
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Economic benefit analysis of primary prevention with pravastatin. Modelling economic benefits after such long term treatment is inappropriate.
    Pharoah P
    BMJ; 1998 Apr; 316(7139):1241-2. PubMed ID: 9553009
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.